Atopic Dermatitis, Healthy Volunteer, Hidradenitis Suppurativa
Conditions
Keywords
Atopic Dermatitis, Hidradenitis Suppurativa, Immune-inflammatory diseases
Brief summary
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases. This first-in-human (FIH) study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of KT-474 in healthy volunteers and patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS). The effects of food on the absorption of KT-474 will also be evaluated in healthy volunteers.
Detailed description
This is a first-in-human (FIH), Phase 1 randomized, placebo-controlled, single and multiple ascending dose trial of KT-474 that will characterize the safety, PK and PD of orally administered KT-474 after a single dose (Part A) and after repeated dosing first in healthy adult volunteers (Part B) and then in patients with AD or HS (Part C). Initially, a dose range of KT-474 in single ascending dose (SAD) escalation cohorts will be explored in healthy subjects. Up to five single dose cohorts of healthy subjects is also planned to understand food effects (FE) on the PK of KT-474. Enrollment of healthy subjects into 2-week multiple ascending dose (MAD) escalation cohorts will be initiated once sufficient safety and PK data from multiple SAD cohorts are available to inform the safe starting dose for the 2-week MAD portion of the study. After the MAD portion in healthy subjects is completed, the safety, PK, and PD of a dose of KT-474 that was found to be safe in healthy subjects when administered for 2 weeks will then be evaluated in AD or HS subjects for 28 days of dosing. Separately, additional multiple dose cohorts evaluating once every other day and/or twice weekly dosing schedules at or below previously evaluated dose levels in healthy volunteers may be initiated.
Interventions
DRUGKT-474/Placebo
KT-474 or matching placebo oral tablet(s)
DRUGKT-474
KT-474 oral tablet(s)
Sponsors
Kymera Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
randomized double blind (for Parts A and B only)
Intervention model description
Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy Volunteer (Parts A and B) Inclusion Criteria: 1. Male and female subjects, including female subjects of child bearing potential, between the ages of 18 and 55 with a weight at least 50 kg and a body mass index (BMI) between 18.0 and 30.0 kg/m2. 2. Subjects confirmed as negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection test at Screening and on Day -2. 3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. 4. Agreement and ability to comply with all contraception requirements if applicable. 5. All subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Healthy Volunteer (Parts A and B)
Exclusion criteria
1. Evidence or history of a clinically significant medical condition or other condition that might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study. 2. Healthy volunteers who have a clinically relevant history or presence of respiratory, GI, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders. 3. Healthy volunteers who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease. 4. Female Healthy volunteers who are pregnant, trying to become pregnant or lactating or breastfeeding. 5. Healthy volunteers who have participated in any investigational drug or device clinical study within 3 months prior to first dosing on this study. 6. Healthy volunteers who have previously participated in a study with an investigational product or device involving the dosing of a biological targeted at any immune pathway within 1 year prior to Screening. AD or HS Patient (Part C) Inclusion Criteria: 1. Male or female patients aged 18 years to 55 years (inclusive) at the time of Screening, and in generally good health, except for AD or HS, and has a BMI of 17.5 to 35.0 kg/m2; and a total body weight \>50 kg (110 lb). 2. Diagnosis of AD or HS for at least 6 months. 3. Patients with AD: having at least 10% treatable percentage body surface area at Screening or on Admission (excluding the scalp and designated venous access areas). 4. Willingness and ability to comply with all contraception requirements as applicable based on reproductive status. 5. Has adequate venous access with venous access sites having AD-unaffected, non-infected skin to permit repeated PK sampling. 6. Female patients must have a negative result for the serum pregnancy test at the Screening Visit and on admission. 7. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. 8. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 9. Patients with HS: A total Abscess and Inflammatory Nodule count of ≥4 at baseline AD or HS Patient (Parts C)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of treatment emergent Adverse Events | up to 28 days |
| Incidence and frequency of use of concomitant medication | up to 28 days |
Secondary
| Measure | Time frame |
|---|---|
| Time to maximum observed plasma concentration (Tmax) | up to 28 days |
| Apparent volume of distribution (Vz/F) | up to 28 days |
| Terminal elimination half-life (t1/2) | up to 28 days |
| Mean residence time (MRT) | up to 28 days |
| Renal clearance (CLR) | up to 28 days |
| Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)] (single dose only) | up to 28 days |
| Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)] | up to 28 days |
| Area under the plasma concentration-time curve during a dosing interval [AUC(0-tau)] | up to 28 days |
| Maximum observed plasma concentration (Cmax) | up to 28 days |
| Apparent clearance (CL/F) | up to 28 days |
Other
| Measure | Time frame |
|---|---|
| Percentage Change from baseline in Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale (NRS) and Investigator Global Assessment (IGA) in AD patients | up to 42 days |
| Percentage Change from baseline in Total Abscess and Inflammatory Nodule (AN) Count, Skin Pain Numerical Rating Scale (NRS), Peak pruritis NRS, and HS Physician's Global Assessment (HS-PGA) in HS patients | up to 42 days |
| IRAK4 levels in peripheral blood mononuclear cells | up to 28 days |
| IRAK4 levels in skin | up to 28 days |
Countries
United States
Outcome results
None listed